DavidEKelleyMD
Endocrinology • Pittsburgh, PADiabetes, Lipid Metabolism
Vice President, Franchise Integrator for Diabetes & Obesity
Are you Dr. Kelley?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 51 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3601 5th Ave
Pittsburgh, PA 15213Phone+1 412-383-8700
Summary
- Dr. David Kelley, MD is an endocrinologist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in New Jersey. He is a Vice President at Franchise Integrator for Diabetes & Obesity.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1987
University of MarylandResidency, Internal Medicine, 1979 - 1981
Oregon Health & Science University (OHSU Health)Internship, Internal Medicine, 1978 - 1979
University of Maryland School of MedicineClass of 1978
Certifications & Licensure
NJ State Medical License 2008 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- PET Imaging of Regional Variation in Insulin Sensitivity of Adipose Tissue in Humans Start of enrollment: 2005 Apr 01
- Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus Start of enrollment: 2004 Jan 01
- Multi-Tracer PET Quantitation of Insulin Action in Muscle (Phase 1, Phase 2, Phase 3, Phase 4) Start of enrollment: 2002 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMuscle insulin resistance in type 1 diabetes with coronary artery disease.Katherine V. Williams, Christina M. Shay, Julie C. Price, Bret H. Goodpaster, Carol Kelley
Diabetologia. 2020-09-14 - 25 citationsProspective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypassJonathan Q. Purnell, Geoffrey S. Johnson, Abdus S. Wahed, Chiara Dalla Man, Francesca Piccinini
Diabetologia. 2018-02-10 - 30 citationsChanges in skeletal muscle and organ size after a weight-loss intervention in overweight and obese type 2 diabetic patients.Dympna Gallagher, David E. Kelley, John C. Thornton, Lawrence M. Boxt, Xavier Pi-Sunyer
The American Journal of Clinical Nutrition. 2017-01-01
Press Mentions
Potential Diabetes Target Makes Subtle Changes with Big Impact on Metabolic HealthJuly 5th, 2019
Tiny Change Has Big Effects, Reverses Prediabetes in MiceJuly 4th, 2019
Subtle Chemical Shift Reverses Prediabetes in Merck-Partnered Mouse TrialJuly 2nd, 2019- Join now to see all
Grant Support
- Mitochondrial Impairment In Muscle Insulin ResistanceNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2006
- Obesity/Nutrition Research CenterNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2006
- PET Imaging Of Regional Variation In Insulin Sensitivity Of Fatty Tissues HumansNational Center For Research Resources2005
- Multi-Tracer PET Quantitation Of Insulin Action In MuscleNational Center For Research Resources2005
- Multi-Tracer PET Quant Skeletal Muscle Insulin Resist Type 2 Diabetes MellitusNational Center For Research Resources2005
- Mitochondrial Impairment In Muscle Insulin ResistanceNational Center For Research Resources2005
- Look Ahead: Ancillary Study: MRI Derived Organ Tissue Mass Weight LossNational Center For Research Resources2005
- Look Ahead Ancillary Study: Fat Cell Size, Muscle Lipid InfiltrationNational Center For Research Resources2005
- Mitochondrial Impairment In Muscle Insulin ResistanceNational Center For Research Resources2004–2005
- Look Ahead Study: Action For Health In DiabetesNational Center For Research Resources2004–2005
- Look Ahead Ancillary Study: MRI Derived Organ And Tissue Mass Changes WithNational Center For Research Resources2004–2005
- Study Of Health Outcomes Of Weight-Loss (SHOW)National Institute Of Diabetes And Digestive And Kidney Diseases2003–2005
- PET Quant Skeletal Muscle Insulin Resist NIDDMNational Center For Research Resources2004
- Multi-Tracer PET Quantitation Of Insulin In MuscleNational Center For Research Resources2004
- Look Ahead: MRI Derived Organ/Tissue Weight LossNational Center For Research Resources2004
- Look Ahead: Fat Cell Size, Muscle Lipid InfiltrationNational Center For Research Resources2004
- Contrast Enhanced US Capillary Recruit MuscleNational Center For Research Resources2004
- Multi-Tracer PET Quantitation Of Insulin ActionNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2004
- Skeletal Muscle Metabolism Of Fatty AcidsNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2004
- Glucagon Receptor Antagonist BAY 27 9955 In NIDDMNational Center For Research Resources2000–2002
- Clinical Center For Look Ahead: Health In DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
- Troglitazone, Metformin, &Sulfonylurea In Insulin Stimulated GlucoseNational Center For Research Resources1999–2002
- SDZ Djn608 &Glyburideon In Basal &Postprandial Hepatic GlucoseNational Center For Research Resources1999–2002
- Effects Of Obesity On Muscle FFA UtilizationNational Center For Research Resources1999–2002
- Lipid Metabolism In Pregnancy And With PreeclampsiaNational Center For Research Resources1998–2002
- Examination Of Skeletal Muscle Fat Content By Mri--Efects Of Obesity And NIDDMNational Center For Research Resources1998–2002
- Core--Clinical Assessment FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases1996–2002
- Effects Of NIDDM On Glucose Transport In Skeletal MuscleNational Center For Research Resources1996–2002
- Obesity Effects On Muscle FFA UtilizationNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2001
- Clinafloxacin Effects On Sulfonylurea Control Of Glucose In NIDDMNational Center For Research Resources1998–2000
- Troglitazone, Metformin &Sulfonylurea And Insulin Stimulated GlucoseNational Center For Research Resources1999
- Effects Of Obesity On Muscle Free Fatty Acid UtilizationNational Center For Research Resources1999
- FFA Metabolism By Skeletal Muscle In Niddm--Regulation By Short Term CaloriesNational Center For Research Resources1998–1999
- Single Dose Study In Healthy Volunteers To Determine The Effect Of ClinafloxacinNational Center For Research Resources1997–1999
- Effects Of Visceral Obesity On Muscle FFA MetabolismNational Center For Research Resources1996–1999
- Six-Month Double-Blind Placebo-Controlled Study Of Troglitazone In NIDDMNational Center For Research Resources1996–1997
- Visceral Obesity Effect On Muscle FFA UtilizationNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1997
- Skeletal Muscle Free Fatty Acid Uptake And Oxidation In ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases1996
- Skeletal Muscle FFA Oxidation During Exercise In NIDDMNational Center For Research Resources1996
- Placebo-Controlled Safety And Efficacy Study Of Pimagedine In Type II DiabetesNational Center For Research Resources1996
- In Vivo Assessment Of Skeletal Muscle Glucose Transport In NIDDMNational Center For Research Resources1996
